Company information Country * Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctic Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Bulgaria Burkina Faso Burundi Cabo Verde Cambodia Cameroon Canada Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of the Cook Islands Costa Rica Croatia Cuba Curaçao Cyprus Czechia Côte d'Ivoire Denmark Djibouti Dominica Dominican Republic, The Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Honduras Hong Kong Hungary Iceland India Indonesia Iran, The Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Republic of Korea, The Democratic People's Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Romania Russian Federation Rwanda Réunion Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French Part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch Part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Åland Islands
Sector Bioinformatics & Data Analytics Diagnostics Digital Health Digital Therapeutics Healthcare Services Life Sciences Medtech & Imaging Prevention Therapeutics
Disease domain Oncology Infectious Diseases Genetic Disorders Chronic Conditions Tech-Enabled Healthcare Services Other
FDA designation Breakthrough - FDA Fast Track - EMA Fast Track - FDA Orphan - FDA Orphan - EMA PRIME - EMA Rare Pediatric Disease - FDA Rare Disease - FDA Rare Disease - EMA None Regenerative Medicine Advanced Therapy - FDA
Company Type Private - C-Corp Private - LLC Private - B-Corp Public Private - Not Yet Incorporated Private - German AG
Pediatric population focus (we consider opportunities that have the potential to enter the pediatric patient population within the investment horizon of the Fund) YES - Current Focus YES - In Horizon NO - May Consider NO - Will Not Target Pediatrics
Previous round financing stage Seed Series A Series B Series C Series D Series E Crossover / PIPE Late Stage PE Public Acquired/Exited
Previous round(s) description
FDA regulatory pathway? Yes No Not Applicable - N/A
FDA review status FDA Not Yet Engaged FDA Engaged FDA In Review FDA Authorized EMA Not Yet Engaged EMA Engaged EMA In Review EMA Authorized Not Applicable - N/A
Past research achievements
What Research has been completed to date? Detail the trial protocol implemented as well as the endpoints achieved for both pre-clinical and, if applicable, human studies
What Portfolio/Pipeline research is to be pursued? What is the current R&D and program management plan? Protocol?
Pediatric innovation strategy
Proposed deal information Stage of current financing Early Stage [Series A] Growth Stage [Series B-C] Crossover Early Stage [Seed]
Use of proceeds description *
Referred by: Advisory Firm Conference Direct Company Submission HIC Centers of Excellence HIC Investment Committee HIC Other Strategic Partner HIC Personnel HIC Physician Advisory Board HIC Strategic Advisory Board Investment Banker LinkedIN Direct VF Candidate Submission Alan Gilbert (LiquidSMARTS) LiquidSMARTS